These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 16234629)

  • 1. The clinical significance of endothelial dysfunction.
    Landmesser U; Drexler H
    Curr Opin Cardiol; 2005 Nov; 20(6):547-51. PubMed ID: 16234629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological approaches to improve endothelial repair mechanisms.
    Besler C; Doerries C; Giannotti G; Lüscher TF; Landmesser U
    Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1071-82. PubMed ID: 18793110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Change of endothelial function with aging].
    Ohnaka K; Takayanagi R
    Nihon Rinsho; 2005 Jun; 63(6):989-93. PubMed ID: 15948380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress.
    Higashi Y; Chayama K; Yoshizumi M
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):133-48. PubMed ID: 15853700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches.
    Tousoulis D; Simopoulou C; Papageorgiou N; Oikonomou E; Hatzis G; Siasos G; Tsiamis E; Stefanadis C
    Pharmacol Ther; 2014 Dec; 144(3):253-67. PubMed ID: 24928320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial dysfunction: potential clinical implications.
    Tousoulis D; Koutsogiannis M; Papageorgiou N; Siasos G; Antoniades C; Tsiamis E; Stefanadis C
    Minerva Med; 2010 Aug; 101(4):271-84. PubMed ID: 21030938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress and endothelial dysfunction: therapeutic implications.
    Gori T; Münzel T
    Ann Med; 2011 Jun; 43(4):259-72. PubMed ID: 21284528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of statin use on endothelial function: from bench to clinics.
    Martínez-González J; Badimon L
    Curr Pharm Des; 2007; 13(17):1771-86. PubMed ID: 17584107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis.
    Candido R; Zanetti M
    Ital Heart J; 2005 Sep; 6(9):703-20. PubMed ID: 16212072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapies targeting vascular endothelium.
    Tousoulis D; Antoniades C; Koumallos N; Marinou K; Stefanadi E; Latsios G; Stefanadis C
    Endothelium; 2006; 13(6):411-21. PubMed ID: 17169773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide-mediated endothelial dysfunction--is there need to treat?
    Tiefenbacher CP; Kreuzer J
    Curr Vasc Pharmacol; 2003 Jun; 1(2):123-33. PubMed ID: 15320839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis.
    Herman AG; Moncada S
    Eur Heart J; 2005 Oct; 26(19):1945-55. PubMed ID: 15911567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase.
    Landmesser U; Engberding N; Bahlmann FH; Schaefer A; Wiencke A; Heineke A; Spiekermann S; Hilfiker-Kleiner D; Templin C; Kotlarz D; Mueller M; Fuchs M; Hornig B; Haller H; Drexler H
    Circulation; 2004 Oct; 110(14):1933-9. PubMed ID: 15466656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities.
    Thomas SR; Witting PK; Drummond GR
    Antioxid Redox Signal; 2008 Oct; 10(10):1713-65. PubMed ID: 18707220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R
    Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current pharmacological approach to restore endothelial dysfunction.
    Dobarro D; Gómez-Rubín MC; Sanchez-Recalde A; Moreno R; Galeote G; Jimenez-Valero S; Calvo L; López de Sá E; López-Sendón JL
    Cardiovasc Hematol Agents Med Chem; 2009 Jul; 7(3):212-22. PubMed ID: 19689260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors.
    Urbich C; Dimmeler S
    Kidney Int; 2005 May; 67(5):1672-6. PubMed ID: 15840010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does reversal of oxidative stress and inflammation provide vascular protection?
    Koh KK; Oh PC; Quon MJ
    Cardiovasc Res; 2009 Mar; 81(4):649-59. PubMed ID: 19098298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renin-angiotensin system in atherosclerosis].
    Fukuda D; Sata M
    Nihon Rinsho; 2006 Apr; 64(4):805-9. PubMed ID: 16613201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Asymmetric dimethylarginine and endothelial dysfunction].
    Yoshizumi M
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():555-60. PubMed ID: 15506448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.